The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro
Abstract
The atypical antipsychotic olanzapine has relatively high affinity for a number of neuronal receptors in radioreceptor binding assays. The ability of olanzapine to activate or antagonize a number of neuronal receptors was investigated in vitro, in cell lines transfected selectively with receptor subtypes and in receptor-selective isolated tissue studies. Olanzapine had no agonist activity at any of the receptors examined. However, olanzapine was a potent antagonist of 5-HT-stimulated increases in IP3 in cell lines transfected with 5-HT2A or 5-HT2B receptors with IC50 values of 30-40 nM. Olanzapine weakly blocked 5-HT-induced formation of IP3 in cell lines transfected with 5-HT2c receptors, but in this cell line potently inhibited 5-HT-stimulated [35S]GTP gamma S binding with a Ki value of 15 nM. Olanzapine blocked dopamine-stimulated adenylyl cyclase in rat retina with modest potency (Ki = 69 nM), consistent with its relatively low affinity for dopamine D1 receptors. Olanzapine blocked agonist-induced activities at the muscarinic receptor subtypes M1, M2, M3, and M5 with Ki values of 70, 622, 126, and 82 nM, respectively. In studies using cell lines transfected with muscarinic M4 receptors, olanzapine and the atypical antipsychotic clozapine did not have agonist activities as determined with cAMP inhibition and stimulation assays, arachidonic acid release and [35S]GTP gamma S binding assays. However, olanzapine antagonized agonist-induced effects in muscarinic M4 cells with a Ki value of 350 nM. In isolated tissue studies, olanzapine potently blocked agonist-induced effects at alpha 1-adrenergic and histamine H1 receptors (KB = 9 and 19 nM, respectively). Thus, olanzapine was an antagonist at all receptors investigated and was a particularly potent antagonist at 5-HT2A, 5-HT2B, 5-HT2C, alpha 1-adrenergic and histamine H1 receptors. Olanzapine was a weaker antagonist at muscarinic and dopamine D1 receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“probably due to their strong binding to histamine receptors(Bymaster et al., 1999)”
From Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis (2024) · cites this paper as Bymaster et al., 1999
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
DeLÉAN, A., Munson, P. J., & Rodbard, D. (1978) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1978.235.2.e97 · Cited by 2,384
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061
Self-citationOpposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum
Stoof, J. C., & Kebabian, J. W. (1981) · Nature · doi:10.1038/294366a0 · Cited by 920
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes
Peralta, E. G., Ashkenazi, A., Winslow, J. W., Ramachandran, J., & Capon, D. J. (1988) · Nature · doi:10.1038/334434a0 · Cited by 658
Sawaguchi, T., & Goldman‐Rakic, P. S. (1994) · Journal of Neurophysiology · doi:10.1152/jn.1994.71.2.515 · Cited by 649
Cited by
Sorted by citations
Street, J. S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.968 · Cited by 585
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 298
Self-citationAntipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities
McIntyre, R. S., McCann, S., & Kennedy, S. H. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600308 · Cited by 261
Ichikawa, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00312-8 · Cited by 248
Metadata
- Authors
- Bymaster, F.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Bymaster, F
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 1999-05-04
- Volume
- 37
- Issue
- 1
- Pages
- 107-122
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2113107587
- Cited by
- 200
- References
- 62
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 10 · 2014: 5 · 2013: 5 · 2012: 10
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- olanzapine, atypical antipsychotics
- MeSH terms
- Olanzapine, Adenylyl Cyclases, Animals, Benzodiazepines, Cells, Cultured, Cricetinae, Kinetics, Pirenzepine, Receptors, Adrenergic, alpha, Receptors, Histamine H1, Receptors, Muscarinic, Receptors, Serotonin, Retina, Receptors, Dopamine D1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
